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Background: Tumors may develop resistance to specific angiogenic inhibitors via activation of alternative
pathways. Therefore, multiple angiogenic pathways should be targeted to achieve significant angiogenic blockade.
In this study we investigated the effects of a combined application of the angiogenic inhibitors endostatin and
tumstatin in a model of human glioblastoma multiforme.
Results: Inhibitors released by stably transfected porcine aortic endothelial cells (PAE) showed anti-angiogenic
activity in proliferation and wound-healing assays with endothelial cells (EC). Interestingly, combination of
endostatin and tumstatin (ES + Tum) also reduced proliferation of glioma cells and additionally induced
morphological changes and apoptosis in vitro. Microencapsulated PAE-cells producing these inhibitors were applied
for local therapy in a subcutaneous glioblastoma model. When endostatin or tumstatin were applied separately,
in vivo tumor growth was inhibited by 58% and 50%, respectively. Combined application of ES + Tum, in
comparison, resulted in a significantly more pronounced inhibition of tumor growth (83%). cDNA microarrays of
tumors treated with ES + Tum revealed an up-regulation of prolactin receptor (PRLR). ES + Tum-induced
up-regulation of PRLR in glioma cells was also found in in vitro. Moreover, exogenous PRLR overexpression in vitro
led to up-regulation of its ligand prolactin and increased proliferation suggesting a functional autocrine growth
loop in these cells.
Conclusion: Our data indicate that integrin-targeting factors endostatin and tumstatin act additively by inhibiting
glioblastoma growth via reduction of vessel density but also directly by affecting proliferation and viability of tumor
cells. Treatment with the ES + Tum-combination activates the PRLR pro-proliferative pathway in glioblastoma. Future
work will show whether the prolactin signaling pathway represents an additional target to improve therapeutic
strategies in this entity.
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Human glioblastoma multiforme (GBM) is the most com-
mon and malignant type of brain tumors. Current treat-
ment options such as surgical intervention, radiation
therapy or cytotoxic chemotherapy do not significantly
improve the median survival beyond approximately 12 to
18 months for patients with GBM [1,2]. Therefore, the
identification and the development of novel and more
efficient therapeutic approaches remain a crucial task
for this disease.
Since GBM is characterized by particularly high levels
of neovascularization, a therapeutic strategy based on
angiogenic blockade appears to be promising. Actually,
a number of strategies targeting new blood vessel
formation have shown some success in preclinical
models of GBM [3,4] and several clinical trials with
anti-angiogenic agents are ongoing [5]. An important
feature of angiogenesis is the interaction of endothelial
cells (EC) with surrounding extracellular matrix (ECM).
Integrin binding mediates cell adhesion of ECs to
surrounding ECM and regulates their survival, growth
and mobility [6]. Integrins and αVβ5 are predominantly
expressed in proangiogenic ECs [7,8] and especially
integrin αVβ3 has been found to be upregulated in ECs
of GBM tumors [9,10]. Cilengitide, a cyclic pentapeptide
mimicking the Arg-Gly-Asp (RGD) binding site of
integrin ligands, was identified as a potent and selective
integrin antagonist that interfered with binding of ECM
components to αVβ3 and αVβ5 integrins [11]. In pre-
clinical models cilengitide had synergistic therapeutic
effects with radioimmunotherapy in breast cancer and
orthotopic brain tumor models [12,13]. However, ex-
pression of αVβ3 and αVβ5 integrins is not restricted to
activated ECs. Both integrins are also in brain tumor
cells [14-16]. In fact, we have recently shown that cilen-
gitide inhibits integrin-dependent signaling and induces
apoptosis not only in endothelial but also in glioma cells
thereby explaining the profound activity of integrin
inhibitors in this disease [17]. These data suggest that
anti-angiogenic molecules directed towards integrins
may have a multi-targeting effect on both endothelial
and glioma cells.
An additional aspect to be considered for the design of
novel therapeutic strategies against GBM is the ability of
these tumors to escape anti-angiogenic monotherapy
[18,19]. Therefore, it might be necessary to target multiple
pro-angiogenic pathways in order to achieve significant
anti-tumorigenic effects.
Here, we studied two angiogenic inhibitors targeting dif-
ferent angiogenic pathways, endostatin (ES) and tumstatin
(Tum), and evaluated the anti-tumorigenic activity of the
individual factors and a combination of both factors in an
in vivo model of GBM. ES has been reported to interfere
with integrin α5β1 and VEGFR-2 in ECs, while Tum bindsαvβ3 and αVβ5 integrins and induces apoptosis in ECs
[20,21]. In addition, microarray analysis of tumor tissue
was performed to identify activation of alternative pro-
tumorigenic signalling pathways in tumor cells.
Results
Encapsulation of stably transfected PAE cells expressing
angiogenic inhibitors and functional analyses in vitro
The expression of ES and Tum in the CM from stably
transfected PAE cells was confirmed by Western blot
analysis (Figure 1A). After cell encapsulation [22,23],
cells in the alginate microbeads were cultured for several
weeks, and the CM analysed by Western blot after
different culture periods to confirm continuous release
of angiogenic inhibitors (Figure 1B).
Next, we tested the functionality of the inhibitors
secreted by the stably transfected PAE cells in prolifera-
tion and wound assays on endothelial cells. CM from
transfected cells decreased proliferation of HUVECs
in vitro when compared to CM from WTcells (Figure 1C).
We observed a moderate reduction on cell proliferation
of ECs incubated with ES containing medium. In com-
parison, CM from Tum transfected cells strongly re-
duced EC numbers to approximately 60% and 35% after 24
and 48 hours, respectively. Next, CM from PAE-WT, -ES,
and -Tum cells were used in a wound assay in vitro.
Compared to CM from WT control cells, media con-
taining the inhibitors decreased wound closure to 13%,
25% and 27% for ES, Tum, and ES + Tum, respectively
(Figure 1D).
Effect of angiogenic inhibitors on glioma cells
In order to analyse whether angiogenic inhibitors exert
direct effects on glioma cells we performed in vitro cell
proliferation and apoptosis assays. Glioma cells and particu-
larly the periphery of high-grade gliomas are known to ex-
press integrins [9]. In line with these data, expression
analyses at the mRNA and protein level of the human gli-
oma cell line G55 showed expression of αVβ3 and α5β1
integrins. (Additional file 1: Figure S1; supplementary data).
Treatment of G55 cells with CM containing either ES
or Tum had only weak inhibitory effects on cell prolifer-
ation. In contrast, CM containing ES + Tum remarkably
reduced G55 cell proliferation to 60-65% compared
to CM containing ES or Tum, alone after 48 hours
(Figure 2A). To evaluate cell viability in response to an-
giogenic inhibitors, G55 cells were analyse with phase-
contrast microscopy and cell apoptosis was measured
using Annexin V/Propidium Iodid staining by FACs
24 hours after treatment. As shown in Figure 2B, G55 cells
presented a normal morphology when cultured in CM
from PAE-WT, PAE-Tum or PAE-ES. In contrast, G55
cells treated with CM containing ES + Tum did not prolif-
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Figure 1 Effects of conditioned medium from encapsulated PAE cells overexpressing ES and Tum. (A) Secretion of ES and Tum from stably
transfected PAE cells was determined using Western blot analysis of culture supernatants after protein concentration with heparin sepharose for ES
and Nickel Cam for Tum. (B) Transfected PAE cells were encapsulated in alginate/PLL as described. Phase contrast photomicrograph shows transfected
cells in microbeads at a magnification of x10. (C) HUVECs cultivated in CM containing ES, Tum or ES + Tum showed reduced proliferation rates when
compared with cells cultivated in CM from PAE WT cells. Bars represent mean values ± SE (n = 3); * on bars indicates significant differences vs. WT
(p < 0.05); */** on connecting lines indicates significant differences between respective groups (p < 0.05 / p < 0.005). (D) Wound healing assay. CM
containing ES, Tum or ES + Tum reduced migration of HDMECs. Wound closure data are normalized to results obtained with CM from PAE WT cells.
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duced similar morphological changes in the glioma cell
lines G44 and G28 (data not shown). CM from ES- or
Tum-transfected cells did not induce increased apoptotic
death of G55 cells when compared to CM from WT cells.
When cultures were treated with CM containing ES +
Tum, in contrast, the frequency of apoptotic G55 cells was
significantly increased by about 23% when compared to
G55 cultures treated with CM from WT control cells
(Figure 2C).
Locally implanted microbeads inhibit subcutaneous
tumor growth
To further investigate the effects of antiangiogenic inhibi-
tors on GBM in vivo, G55 cells were grown subcutaneouslyas xenografts in SCID mice. Tumors were subsequently
treated with angiogenic inhibitors alone or in combination
using microencapsulation technology as described before
[24]. We observed a strong reduction of tumor weight by
about 60% and 50% for ES and Tum treated animals, re-
spectively, when compared with the control group. Inter-
estingly, the ES + Tum combination showed the strongest
reduction of tumor weight of approximately 83% when
compared to control tumors (Figure 3A). Furthermore,
blinded analyses of microvessel density showed a signifi-
cant inhibition of vascularization in ES-treated tumors.
Vessel density in Tum-treated tumors, however, was not
significantly altered (Figure 3B). The combined application
of ES and Tum also resulted in a significantly reduced
microvessel density in G55 tumors.
















































Figure 2 Conditioned medium containing ES + Tum reduced proliferation and induced apoptosis in G55 glioma cells in vitro.
(A) G55 cells were cultivated in CM from PAE WT cells, and in CM containing ES or Tum or ES + Tum. Cell numbers were determined after a
culture period of 24 and 48 hours. Bars represent the means ± SE (n = 3); * on bars indicates significant differences vs. WT; * on connecting
lines indicates significant differences between respective groups (p < 0.05). (B) Phase contrast micrographs of G55 cells after a culture period
of 24 hours in CM from PAE-WT cells or CM containing ES or Tum or ES + Tum. (C) Quantification of apoptotic G55 cells after cultivation in
CM from PAE WT cells or CM containing ES or Tum or ES + Tum using flow cytometric analysis after FITC-conjugated annexin-V and PI
staining.
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mors with absence of large necrotic areas in control
animals. Tum- and ES-treated tumors, in comparison,
were characterized by large necrotic areas with numer-
ous TUNEL-positive cells were observed. Vital cells
were restricted to thin layers surrounding vessels and
to the outer margins of tumors (Figure 3C). A similar
pattern was seen in tumors treated with ES + Tum.cDNA microarrays and target genes of anti-angiogenic
treatment in G55 tumors
We next analysed whether treatments with the different
angiogenic inhibitors induced responses in glioma cells via
differential regulation of alternative cellular pathways. To
address this question we performed cDNA arrays with
mRNA isolated from tumor tissue after treatment with



























































Figure 3 Analysis of G55 tumors treated with ES, Tum and ES + Tum. Effect on tumor growth and tumor vessel density. (A)
Subcutaneously grafted tumors were treated with ES, Tum and ES + Tum for 10 days, tumors were excised and tumor weights determined. Bars
represent the mean values ± SE (n = 5); * on bars indicates significant differences vs. WT; * on connecting lines indicates significant differences
between respective groups (p < 0.05). (B) Microvessel density was analysed by counting CD31-positive vessels in tumor tissue. Note that microvessel
density is significantly reduced in ES- and ES + Tum-treated tumors, but not in Tum-treated tumors. Bars represent the means ± SE (n = 4-5);
* significant differences vs. WT (p < 0.05). (C) Tumor tissue was analysed by H&E, TUNEL and immunohistochemical stainings for Ki67 and CD31.
ES-, Tum- and ES + Tum-treated tumors showed large necrotic areas containing TUNEL-positive cells. Vital cells were restricted to thin cell layers
around vessels (v) and at the outer margins of tumors. Control tumors (WT), in comparison, were highly proliferative and lacked large
necrotic areas.
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ratio ‡1.0) were identified in any of the treated groups.
Based on the fact that standard thresholds might be too
stringent at high intensities [25], we defined a lower signal
log ratio as a threshold and selected some relevant genes
for further validation analysis (Additional file 2: Table S1;
supplementary data). Of those, we considered prolactin
and its receptor appeared as the most interesting candi-
date genes, since this pathway has been reported to be
involved in the progression of several tumor type
[26,27]. Prolactin receptor (PRLR) was found to be up-
regulated (SLR: +0.3) in tumors treated with the ES +
Tum combination when compared to control tumors.
The microarray results were verified in identical mRNAsamples from tumor tissues analysed by quantitative
RT-PCR. Prolactin receptor (PRLR) expression showed
a 2.5 fold up-regulation in tumors treated with the ES +
Tum combination compared to the control group
(Figure 4A). The same tumor material used for micro-
array analyses was histologically analysed for the ex-
pression of PRLR. In contrast to control tumors which
displayed low to moderate staining for PRLR, ES +
Tum-treated tumors showed intense immunoreactivity
for PRLR. PRLR-staining pattern was heterogeneous
and mainly localized in certain tumor regions. Double
immunohistochemical staining for the apoptosis marker
M30 (brown) and PRLR (red) revealed no or few apop-















Figure 4 Expression analyses of prolactin receptor in tumor tissue. (A) Quantitative RT-PCR revealed a 2.5-fold upregulation of prolactin
receptor mRNA expression in ES + Tum-treated tumors when compared to control tumors (B) Upper side: Immunostaining for prolactin receptor
in control tumors (x10) and ES + Tum-treated tumors (left x10; right x40). Lower side: Immunostaining for prolactin receptor and cleaved cytokeratin
(M30) in ES + Tum-treated tumors (x40).
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(Figure 4B).Simultaneous treatment with endostatin and tumstatin of
G55 cells in vitro induces PRLR-up-regulation in G55 cells
in vitro
Glioma cells were treated for 7 days with CM from
PAE-WT cells or a mixture of CM from ES- and Tum-
PAE transfected cells. Subsequent expression analyses
at the mRNA level revealed a 14fold up-regulation of
PRLR in cells stimulated with ES + Tum when com-
pared with the control cells (Figure 5A). Blockade of
integrins αvβ3/αvβ5 with the RGD-peptide cilengitide
(CGT; 5 μg/ml) after 3 days did not affect PRLR ex-
pression, whereas simultaneous treatment with CGT
and the Tum + ES combination blocked the ES + Tum-
induced up-regulation of PRLR (Figure 5B). Immuno-
fluorescence analysis on G55 cells showed cell clusters
with intensive PRLR staining in those cells treated with
ES and Tum, whereas the PRLR level in WT-treated
cells remained low (Figure 5C).PRLR stimulates proliferation and survival of G55
glioma cells
To investigate the potential role of PRLR in glioma
tumor cells, we examined the expression levels and
functionality of endogenous PRLR in two glioma cell
lines (G28 and G55). We detected PRLR mRNA ex-
pression in both G28 and G55 cells (Additional file 3:
Figure S2-A; supplementary data) and observed that
prolactin (PRL), the cognate ligand of the PRLR, stimu-
lated cell proliferation of both cell lines in a dose-
dependent manner (Additional file 3: Figure S2-B; sup-
plementary data). These data indicates that G28 and
G55 cells express a functional PRLR which apparently
exerts a pro-proliferative effect. In a second step and
mimicking the PRLR-up-regulation in ES + Tum treated
tumors in vivo, we overexpressed PRLR in G55 cells
in vitro. Cells were transfected with an expression vector
encoding HA-tagged full length PRLR or with the empty
vector as a control. Overexpression of PRLR in stably
transfected cells was confirmed at the mRNA and protein
level as shown in Figure 6A. Interestingly, we observed a
4,5 fold up-regulation in the expression level of prolactin
14 x







Figure 5 Elevated levels of PRLR mRNA in glioma cells treated with ES + Tum. (A) Quantification of prolactin receptor mRNA expression
revealed a 14-fold increase in G55 cells treated with CM containing ES + Tum when compared to G55 cells treated with CM from PA-WT cells.
(B) Quantification of prolactin receptor mRNA expression in G55 cells treated with CM from PAE-WT, CM containing ES + Tum and cilengitide
(CGT, 5 μg/ml) alone and in combinations. Bars represent the mean values ± SE from three independent experiments. (C) Immunofluorescence
staining for PRLR in G55 cells after treatment with CM from PAE-WT and CM containing ES + Tum.
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(Figure 6A right).
The effect of forced expression PRLR in G55 cells
growth was further examined using the WST-1 colori-
metric assay. Figure 6B illustrates proliferation rates of
PRLR-overexpressing versus control cells after 72 hours
incubation with prolactin and the inhibitor AG-490 in
the absence of serum. Values are given in percent and
are related to the control cells that were incubated with
basal medium only. Under these conditions PRLR-
overexpressing cells showed a significantly increased
proliferation activity (86%) when compared to mock-
transfected cells. Treatment with the ligand PRL at a
concentration of 2 nM induced a minor stimulation of
proliferation of control and PRLR-overexpressing cells
to an extent of 18% and 25%, respectively. In order to
corroborate the PRLR-related increase in cell prolifera-
tion, we administered AG-490, a potent inhibitor of the
Jak2 tyrosine kinase, which is critical for the transmis-
sion of PRLR-mediated proliferative signals [28]. While
AG-490 reduced proliferation of PRLR-overexpressing
cells in a dose dependent manner, it did not significantly
affect proliferation of control cells. Thus, at a concen-
tration of 1 μM AG-490 we observed comparable prolif-
eration rates for PRLR-overexpressing and control cells.In the presence of 2 nM prolactin, higher concentra-
tions of inhibitor AG-490 (10 μM) were necessary to
block the PRLR-related increase of proliferation.
Next, we analysed the effect of ES + Tum treatment in
cells overexpressing PRLR. To this aim, proliferation
rates of PRLR-overexpressing or control cells were deter-
mined in CM containing ES + Tum and related to those
observed in CM from PAE-WT cells. While ES + Tum
dramatically decreased proliferation of control cells to
about 39%, proliferation of PRLR-overexpressing cells
was reduced to only 64% of the control value (Figure 6C).
Additional treatment with the inhibitor AG-490 reduced
proliferation rates of both control and PRLR cells to a
similar extent (i.e. 24% and 15%, respectively).Discussion
Angiogenesis plays a central role in tumor growth and
metastasis. Since GBM tumors are highly vascularised,
therapeutic strategies based on angiogenic blockade are
particularly attractive for this entity. However, it has
been observed that initial responses to anti-angiogenic
therapy are frequently followed by tumor progression
resulting in only limited survival advantage [29-31].
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Figure 6 PRLR overexpression in glioma cells in vitro. (A) Verification of PRLR-overexpression in the glioma cell line G55 using Western blot
analysis and RT-PCR (left). Quantification of PRLR and PRL mRNA expression in stably PRLR-transfected (G55 PRLR) and mock-transfected ((G55 3.1(−))
G55 cells (right). (B) Effect of PRLR overexpression on cell growth in the presence or absence of PRL and the Jak-2 inhibitor AG-490. Bars represent the
mean values ± SE (n = 5-6); ** on connecting lines indicates significant differences between respective groups (p < 0.005). (C) PRLR- and mock- (3.1(−))
transfected G55 cells were treated with CM from PAE-WT or CM containing ES + Tum with and without the Jak-2 inhibitor AG-490. Bars represent the
mean values ± SE (n = 5-6); * on connecting lines indicates significant differences between respective groups (p < 0. 05).
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ways that sustain tumor growth.
Accordingly, our approach was designed to simultan-
eously target different angiogenic signaling pathways
and to investigate the activation of possible resistance
mechanisms in a GBM model.
Our results show for the first time that the combined
application of the integrin inhibitors ES and Tum signifi-
cantly augment the inhibitory effect over each of the in-
dividual substances and that the ES + Tum combination
exerts its antitumorigenic effects by both antiangiogenic
and direct antitumorigenic activities. Finally, we found
an up-regulation of the prolactin receptor in tumor cells
treated with the ES + Tum combination and demon-
strate a role of this receptor in the control of glioma cell
proliferation in vitro.
In the present study, the antiangiogenic substances
were delivered to a subcutaneous graft of G55 glioma
cells using ex vivo modified PAE cells, which were encap-
sulated in alginate microbeads. The microencapsulation
technology ensures a continuous release of proteins, and
has been successfully used by us and others in different
animal models [32,33].
The efficacy of each angiogenic inhibitor was demon-
strated on EC proliferation and wound assays in vitro
and the combination of ES + Tum showed even additive
inhibitory effects on endothelial cell proliferation. Local
release of single inhibitors ES and Tum by encapsulated
PAE cells resulted in inhibition of tumor growth in
subcutaneously implanted GBM by about 58% and 50%,
respectively, when compared to the control group, re-
spectively. Strikingly, the combined application of ES
and Tum inhibited tumor growth by about 83% tumor
growth inhibition.
While these observations correlated with a pronounced
decrease of vascular density in ES- treated tumors, treat-
ment with Tum resulted in only minimal reduction of
blood vessel density, suggesting that in vivo tumor growth
reduction mediated by Tum is mainly caused by a direct
antitumorigenic activities and less through antiangiogenic
mechanisms. A direct αVβ3 -dependent growth-inhibitory
effect of Tum on glioma cells in vitro and in vivo has been
previously describe by Kawaguchi et al. [34]. On the other
hand, the extent of tumor growth inhibition caused by
the Es + Tum combination was higher than expected
compared with the reduction level of vessel density.
This fact prompted us to hypothesize that the ES +
Tum combination exerts direct anti-neoplastic effects
on glioma cells in vivo, in addition to its antiangiogenic
effect. This hypothesis was confirmed in our in vitro
experiments, which showed reduced proliferation rates
of glioma cells after treatment with the ES + Tum
combination, but not after treatment with the single in-
hibitors. Moreover, the ES + Tum combination causedmorphological changes and induced apoptosis in gli-
oma cells. Since previous studies have demonstrated
that integrin antagonists affect cell cycle progression
and viability of glioma cell lines, even inhibiting signal-
ing pathways similar to ECs [34], we suggest that ES
and Tum act through their respective integrin recep-
tors on glioma cells, ultimately leading to inhibition of
proliferation and induction of apoptosis. Nevertheless,
further studies are necessary to clarify the effects of ES +
Tum on glioma cells at the molecular level.
In order to gain further insights into possible mecha-
nisms that enable tumor cells to escape anti-angiogenic
therapies, we performed cDNA arrays using mRNA
from tumor tissue treated with encapsulated PAE-WT
cells or PAE cells releasing ES or Tum, either individu-
ally or in combination. Surprisingly, we identified only a
few genes with a significant increase or decrease in
expression level (mean signal log ratio ‡1.0) in the ES-,
Tum- or ES + Tum-treated groups when compared with
the control group. We focused our interest on the hor-
mone prolactin (PRL) and its cognate receptor PRLR,
which were up-regulated after treatment with Tum and
ES + Tum, respectively. Validation of PRLR up-regulation
in ES + Tum tissue sections by immunohistochemistry re-
vealed a heterogeneous staining pattern with an intensive
PRLR staining localized in well-defined tumor regions.
Double immunostaining with apoptotic marker M30 and
PRLR further showed that those areas with high levels of
PRLR contained none or few apoptotic cells, whereas
apoptotic regions presented low or no expression of PRLR.
Similar results were obtained in vitro after immunofluor-
escence staining for cleaved caspase-3 and PRLR in glioma
cells treated with ES + Tum (data not shown). Based on
these results, we assume that a subpopulation within the
G55 cells does not undergo apoptosis after ES + Tum-
treatment but rather proliferates via activation of the
PRLR/PRL signaling axis. In Glioblastoma “Cancer Stem
Cells” (CSC), a small subpopulation of self-renewing
“stem-like” cancer cells, have been demonstrated to show
resistance to commonly used anticancer therapies such as
radiation [35] and chemotherapy [36,37]. Clark et al. [38]
have observed a compensatory activation of multiple
ERBB family receptors in GBM CSCs deprived of EGFR
signal, suggesting an intrinsic GBM resistance mechanism
for EGFR-targeted therapy. To what extent the PRLR-
positive subpopulation found in ES + Tum-treated tumor
consist of CSC needs to be further investigated in future
studies.
Several studies have documented the involvement of the
ligand PRL in the growth control of different tumors such
as breast [39], liver [40] and prostate [41] and further, PRL
antagonists such as hPRL-G129R has been demonstrated
to inhibit breast cancer growth in vitro and in vivo [42].
However, only little is known about the role of the PRLR/
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been found in rat and human glioma cells [28,43] but also
in benign intracranial tumors [44]. Ducret et al. [45] have
shown that PRL induces a dose-dependent increase in
proliferation and survival of U87-MG glioma cells. In line
with these results we have detected PRLR mRNA
expression in two additional glioma cell lines (G28 and
G55) and could demonstrate that PRL stimulates cell pro-
liferation in a dose-dependent manner, indicating that
these cells express a functional PRLR.
Interestingly, we observed a strong up-regulation of
PRLR in glioma cells treated with ES + Tum in vitro.
PRLR expression in contrast was not influenced by oxygen
deprivation as observed after incubation of G55 cells
under hypoxic and normoxic conditions for 24 hours,
48 hours and 5 days (data not shown). These observations
suggest that up-regulation of PRLR in GBM tumors after
ES + Tum treatment was not a secondary response to the
anti-angiogenic treatment, but rather mediated through
direct action of both integrin targeting factors on tumor
cells. Although little is known about the effects of ES
and Tum on glioma cells at the molecular level, an
integrin-mediated auto-regulation of cell proliferation
and apoptosis in glioma cells have been recently de-
scribed by our group and others [17,34]. In addition, an
integrin-PRLR cross-talk has recently been described in
breast cancer cells [46]. The fact that cilengitide, an in-
tegrin αvβ3/αvβ5 inhibitor, partially blocked ES + Tum-
mediated effect on PRLR expression point to an integrin
dependent mechanism. It is therefore tempting to
speculate that the combined application of ES and Tum
triggers up-regulation of PRLR in glioma, resulting in
augmented PRL signalling and ultimately in increased
tumor growth and/or stimulation of angiogenesis [47].
Our in vitro data confirm to some extent this hypothesis
as they show for the first time that PRLR overexpression
significantly increases glioma cell growth. The PRLR-
mediated increase of cell growth was abrogated by inhib-
ition of Jak2, a tyrosine kinase that has been described
as major downstream regulator of PRLR-signalling [28].
Moreover, we found a 4fold up-regulation of PRL ex-
pression in PRLR-overexpressing cells when compared
to mock-transfected cells, suggesting a PRL-autocrine
loop that stimulates glioma cell growth. Beside the
already mentioned pro-proliferative activity of PRLR in
diverse tumor entities, several groups have reported
about a PRLR/PRL-mediated inhibition of apoptosis es-
pecially in response to chemotherapy. In breast cancer
cells PRL confers resistance against cisplatin by activat-
ing a detoxification enzyme [48,49] and in ovarian car-
cinoma cells PRL and its receptor inhibit apoptosis
induced by serum starvation or cisplatin treatment [49].
These observations might explain the fact that ES +
Tum-mediated cell growth inhibition in vitro wassignificantly less pronounced in PRLR overexpressing
cells than in control cells.
Conclusion
Our current data demonstrate that the integrin inhibitors
ES and Tum significantly reduce GBM growth in vivo. We
also demonstrate that a simultaneous application of ES
and Tum has more pronounced anti-tumorigenic effect
than applications of each factor alone, and that this strong
anti-tumorigenic effect of ES + Tum is likely mediated
by a combination of anti-angiogenic and direct anti-
tumorigenic activities. Moreover, we show that ES + Tum
therapy induces up-regulation of the prolactin receptor in
GBM in vivo and that the activation of PL/PRLR signaling
stimulates proliferation. Additional studies are necessary
to elucidate whether the PRL/PRLR signalling pathway
represents a novel target for therapeutic strategies aimed
at developing effective treatments for GBM.
Material and methods
Expression vectors and transfection procedure
CMV (human cytomegalovirus) promoter driven plamids
were used to generate expression vectors for angiogenic
inhibitors. Murine ES was introduced into pcDNA3.1
plasmid (Invitrogen Life Technologies, Carlsbad, CA) as
described previously [32]. The cDNA coding for Tum was
obtained by RT-PCR from total RNA extracted from
HDMECs (human dermal microvascular endothelial cells)
using following primer-pair: forward-primer 5′ccgagctcg-
gatccaggtttgaaaggaaaa3′ and reverse-primer 5′cgctcgagggt
gtcttttcatgcacacct3′, and was cloned into pSecTag2/Hygro
(Invitrogen Life Technologies). The cDNA encoding full
length PRLR together with a C-terminal HA-tag was
cloned in pcDNA3.1(−)/Hygro plasmid (Invitrogen Life
Technologies). The PRLR cDNA was obtained by RT-PCR
from total RNA extracted from the cell line MCF-7
using following primer-pair: forward-primer 5′aacactcgaga
aggcagccaacatgaaggaaaat3′ and reverse-primer: 5′tgggtacc
ttaagcgtaatctggaacatcgtatgggtagtgaaaggagtgtgt3′. Porcine
aortic endothelial (PAE) cells were transfected with 2 μg
plasmid DNA (ES, Tum), and the glioma cell line G55
with 1 μg plasmid DNA (PRLR) using Lipofectamine
Plus® (Invitrogen Life Technologies) according to manu-
facturer instructions. Positive cells were selected by appli-
cation of the appropriate antibiotics, and again expanded.
Cell culture and microencapsulation
Commercially available HUVECs and HDMECs were
cultured in EGM-2 medium (Lonza, Basel, Switzerland)
containing 2% fetal calf serum (FCS). PAE cells were
maintained in F-12/HAM medium supplemented with 10%
FCS. The human glioblastoma cell line G55 [50] was kindly
provided by Prof. Katrin Lamszus from the Department of
Neurosurgery, University Hospital Hamburg-Eppendorf,
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with 10% FCS. All cells were maintained in 5% CO2/
95% air atmosphere in a humidified incubator at 37°C.
Wild-type or stably transfected PAE cells were encapsu-
lated in Alginat microbeads as described previously
[22,23]. Cells were resuspended in a 2% sodium algin-
ate–saline solution (Pronova Ultra-Pure MVG; FMC
BioPolymer AS d/b/a NovaMatrix, Sandvika, Norway)
to a final concentration of 2 × 106 cells/ml. For in vitro
experiments conditioned medium (CM) was collected
after a culture period of 48 hours. For long stimulation
experiments CM was collected after a culture period of
4 days and subsequently diluted 1:3 with serum-reduced
medium.Cell viability and proliferation assay
HUVEC and G55 cells (5 × 104 per well) were seeded on
48-well tissue culture plates and incubated in basal
medium or in CM or mixtures of CM from PAE-WT,
PAE-Tum and PAE-ES cells additionally containing 4%
FCS. Each stimulation experiment was performed in
triplicate. After 24 and 48 hours of incubation at 37°C,
cells were trypsinized and counted using the Vi-Cell XR
(Beckman Coulter, Germany).
Cellular viability and proliferation was assessed using
the WST-1 assay (Roche Applied Science, Mannheim,
Germany) following the manufacturer´s instructions.
Stably PRLR-transfected or mock-transfected G55-WT
or G55 cells (8 × 103 cells per well) were cultured under
serum deprivation in presence of AG490 (0.1, 1 and
10 μM) and/or 2 nM prolactin (R&D Systems, Minneapolis,
MN). To quantify cell viability, cells were incubated
with WST-1 reagent for 1 h and the absorbance was
measured using a plate reader at 450 nm (reference
650 nm). Each stimulation experiment was performed
in quintuplicate. Cell viability of experimental cells was
related to cell viability of control (untreated) cells,
which was set to 100%.Apoptosis assay
G55 cells were seeded at subconfluent density into multi-
well tissue culture plates. After culture overnight, cells
were washed twice with PBS, and medium was replaced
with CM from PAE-WT, PAE-Tum or PAE-ES cells, or a
mixture of CM from PAE-Tum and PAE-ES cells. Incuba-
tions of cultures were continued for 24 hours before cells
were analysed for apoptosis. For analysis, adherent cells
were detached and pooled with floating cells. Apoptosis
was assessed by flow cytometric analysis of cells stained
with FITC-conjugated annexin-V and PI (BD Biosciences
Pharmigen, San Diego, CA). Values represent the mean of
three independent experiments.Western blotting
Supernatants of transfected PAE cells were tested for
transgene expression using Western blot analysis. CM
from PAE-ES cells was incubated overnight at 4°C with
heparin agarose (Sigma-Aldrich, St. Louis, MO) for pro-
tein concentration. Supernatant of PAE-Tum cells were
concentrated overnight at 4°C by Nickel Cam™ HC resin
(Sigma-Aldrich) according to manufacturer instructions.
ES, Tum and PRLR were detected by murine ES poly-
clonal antibody (R&D Systems) [24], His-probe polyclonal
antibody (Santa Cruz Biothechnology, Santa Cruz, CA)
[24] and HA antibody (H6908; Sigma-Aldrich), re-
spectively. The signal was visualized by Lumigen™ PS-3
detection reagent (GE Healthcare, Buckinghamshire,
UK)) and exposed to an Amersham Hyperfilm™ECL
(GE Healthcare).
In vitro wound healing assay
HDMEC cells (7× 105) were cultured in 24-well tissue
culture plates in endothelial growth medium with sup-
plements. After reaching confluence each well was
scratched with a standardized pipette tip, resulting in an
EC-free wound. Medium was replaced with CM of WT
or transfected PAE cells additionally supplemented with
4% FCS. Photographs of each well were taken direct
after scratching and after 20 hours incubation. The
width of the gap was determined using AxioVision40
V4.8 software (Carl Zeiss Imaging Solutions, Jena,
Germany) and values representing the closing wound
were compared between experimental groups. Values
represent the mean of three independent experiments.
In vivo tumor model
Animal experiments were conducted according to the
UKCCR guidelines for the welfare of animals in experi-
mental neoplasia [51]. G55 cells (1× 106) were subcuta-
neously injected into SCID mice. Microbeads containing
1 × 106 WT or transfected PAE cells were implanted at
the same site 7 days later. In the combination groups
1 × 106 PAE cells producing each inhibitor were injected.
Each experimental group consisted of 5 animals. After
10 days, animals were sacrificed and tumors were ex-
cised and weighed. One half of each tumor was fixed in
10% formaldehyde and embedded in paraffin for immu-
nohistochemistry. The other half was frozen in liquid
nitrogen and used for RNA isolation.
Immunohistochemistry and immunofluorescence
Paraffin-embedded tissue samples were serially sectioned
at a thickness of 5 μm, and every 20th section was used
for analysis. Tissue sections were consecutively stained
with hematoxylin and eosin. Blood vessels were visualized
using murine polyclonal CD31 antibody [52] (Dianova,
Hamburg, Germany). Monoclonal Ki67 [52], polyclonal
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purchased from Dako (Dako Denmarck A/S, Glostrup,
Denmark), abcam (Cambridge, UK) and Roche Applied
Science respectively. Immunhistochemical staining was
performed as previously described [52]. For double
immunhistochemical analyses, M30 and PRLR anti-
bodies were visualized with Diaminobenzidine (DAB)
and 3-Amino-9-ethylcarbazole (AEC), respectively. A
blocking step in between using the Avidin-Biotin Block-
ing Kit (Vector Laboratories, Inc., Burlingame, CA) was
performed. For immunofluorescence detection of PRLR
in G55 cells, 3× 105 cells were seeded on chamber slides
and treated with CM or mixtures of CM from PAE-WT,
PAE-Tum and PAE-ES cells for 3 days. After fixation
with cold ice methanol, staining was performed as pre-
viously described [52]. Microvessel density was quanti-
fied by counting CD31-positive vessels in 10 arbitrarily
chosen visual fields (10 × magnification) per tumor
from totally 4 to 5 tumors from each experimental
animal group using AxioVision40 V4.8 software (Carl
Zeiss Imaging Solutions, Jena, Germany).
TUNEL assay of apoptotic cells
For the in situ detection of fragmented DNA, tissue sec-
tions were subjected to terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) using the in situ
cell death detection kit, POD (Roche Diagnostic GmbH)
according to the manufacturer´s instructions. Nuclei
were counterstained with haematoxylin. TUNEL-negative
nuclei were stained blue, while TUNEL-positive nuclei
were stained brown.
RNA isolation and microarray analysis
Frozen tumor samples were homogenized with a micro
tissue disintegrator. Tissue homogenates were first treated
with Tri®Reagent (Sigma-Aldrich) for RNA Isolation
succeeded by purification with the RNeasy Mini Kit
(Qiagen, Hilden, Germany) following manufactures
protocols. Quality and concentration of isolated RNA
was determined using the Agilent RNA 6000 Nano Kit
(Agilent Technologies Inc., Waldbronn, Germany) and
NanoDrop6000 Photometer (Peqlab Biothechnologie
GmbH, Erlangen, Germany). From each experimental
animal group, three RNA samples were selected for
further microarray analyses. Sense strand cDNA was
generated from 100 ng total RNA using the Ambion
WT Expression Kit (Ambion Inc., Applied Biosystems,
Austin, TX). Procedures for labelling, fragmentation
and hybridization were performed using the Terminal
Labeling Kit and Hybridization, Wash and Stain Kit
following Affymetrix protocols. All experiments were
performed using Affymetrix Human Gene 1.0 ST Array
containing 28.869 genes (Affymetrix Inc., Santa Clara,
CA). Microarrays were scanned with the GeneChipScanner 3000 7G (Affymetrix Inc.) using the GeneChip
Command Console 3.0 (Affymetrix Inc.). The signals
were processed using Genelevel RMA Sketch algo-
rithm with following software: Affymetrix® Expression
Console™ 1.1 software. Comparison analyses were car-
ried out with a T-Test (between subjects) (TIGR, The
Institute for Genomic Research, MeV 4).
Statistical analysis
Statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS) program (SPSS Inc.
Chicago, IL, USA), version 15 with a Mann–Whitney-U-
Test for tumor growth, microvessel density data and
wound assays and with the unpaired Student t test with
Welch correction for proliferation experiments. Prob-
ability value (p-value) ≤ 0.05 was considered statistically
significant.
Additional files
Additional file 1: Figure S1. Expression analyses of αVβ3 and α5β1
integrins in G55 cells. Endogenous expression of αVβ3 and α5β1 integrins
in G55 cells was detected (PDF 50 kb) at the mRNA level using RT-PCR
(A) and at the protein level using Flow Cytometry Analyses (B). Control
Integrin αVβ3 Control Integrin α5β1.
Additional file 2: Table S1. Differentially regulated genes in G55 tumos
after treatment with angiogenic inhibitors.
Additional file 3: Figure S2. Effect of PRL on glioma cell proliferation.
Endogeneous PRLR expression at mRNA level was detected in both G28
and G55 cells using RT-PCR (A). Human breast cancer cell line T47D was
used as a positive control. Prolactin (PRL) stimulated cell proliferation of
both cell lines in a dose-dependent manner (B). Bars represent the mean
values ± SE (n = 5-6); * on bars indicates significant differences vs. control
(p < 0. 05).
Abbreviations
CGT: Cilengitide; CM: Conditionated medium; EC: Endothelial cells;
ES: Endostatin; GBM: Glioblastoma Multiforme; HDMEC: Human dermal
microvascular endothelial cells; PAE: Porcine aortic endothelial cells;
PRL: Prolactin; PRLR: Prolactin receptor; Tum: Tumstatin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LOF, JW, GS and WF designed this research work. LOF, JH and MK performed
experiments and analysed data in this manuscript. LOF, JW, UB, EMMP, WF,
CB and GS interpreted the data and wrote the manuscript. All authors read
and approved the final manuscript.
Acknowledgments
We thank Bettina Petrowitz and Anne Schlüter for their contributions to this
project. In addition we appreciate the help of Dr. Thomas Streichert,
Dr. Benjamin Otto und Kristin Klätschke from the Microarray Core-Facility in UKE.
This work was supported by Deutsche Krebshilfe.
Author details
1Department of Oncology, Hematology and Bone Marrow Transplantation
with Section Pneumology, University Cancer Center Hamburg (UCCH),
Universtity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
2Department of Gynecology University Cancer Center Hamburg (UCCH),
University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
3Department of Ophthalmology, University Medical Center
Oliveira-Ferrer et al. Molecular Cancer 2013, 12:144 Page 13 of 14
http://www.molecular-cancer.com/content/12/1/144Hamburg-Eppendorf, Hamburg, Germany. 4Institute of Human Genetics,
Christian-Albrechts-University of Kiel & University Hospital Schleswig-Holstein,
Campus Kiel, Kiel, Germany.
Received: 20 November 2012 Accepted: 13 November 2013
Published: 20 November 2013
References
1. Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS:
Cancer surveillance series [corrected]: brain and other central nervous
system cancers: recent trends in incidence and mortality. J Natl Cancer
Inst 1999, 91:1382–1390.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med
2005, 352:987–996.
3. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC:
PTK787/ZK222584, an inhibitor of vascular endothelial growth factor
receptor tyrosine kinases, decreases glioma growth and vascularization.
Neurosurgery 2004, 55:426–432.
4. Szentirmai O, Baker CH, Bullain SS, Lin N, Takahashi M, Folkman J, Mulligan
RC, Carter BS: Successful inhibition of intracranial human glioblastoma
multiforme xenograft growth via systemic adenoviral delivery of soluble
endostatin and soluble vascular endothelial growth factor receptor-2:
laboratory investigation. J Neurosurg 2008, 108:979–988.
5. Anderson JC, McFarland BC, Gladson CL: New molecular targets in
angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med 2008,
10:e23.
6. Stupack DG: The biology of integrins. Oncology (Williston Park) 2007,
21:6–12.
7. Hood JD, Cheresh DA: Role of integrins in cell invasion and migration.
Nat Rev Cancer 2002, 2:91–100.
8. Kumar CC: Integrin alpha v beta 3 as a therapeutic target for blocking
tumor-induced angiogenesis. Curr Drug Targets 2003, 4:123–131.
9. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP: Comparison of cell
adhesion molecule expression between glioblastoma multiforme and
autologous normal brain tissue. J Neuroimmunol 1995, 57:143–153.
10. Gladson CL: Expression of integrin alpha v beta 3 in small blood vessels
of glioblastoma tumors. J Neuropathol Exp Neurol 1996, 55:1143–1149.
11. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A,
Goodman SL, Kessler H: N-Methylated cyclic RGD peptides as highly
active and selective alpha(V)beta(3) integrin antagonists. J Med Chem
1999, 42:3033–3040.
12. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL:
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with
radioimmunotherapy to increase efficacy and apoptosis in breast cancer
xenografts. Cancer Res 2002, 62:4263–4272.
13. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug
WE: Preferential susceptibility of brain tumors to the antiangiogenic
effects of an alpha(v) integrin antagonist. Neurosurgery 2001, 48:151–157.
14. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF,
Villani R, Cheresh DA, Black PM: Alpha(v)beta3 and alpha(v)beta5 integrin
expression in glioma periphery. Neurosurgery 2001, 49:380–389.
15. Paulus W, Baur I, Schuppan D, Roggendorf W: Characterization of integrin
receptors in normal and neoplastic human brain. Am J Pathol 1993,
143:154–163.
16. Lim M, Guccione S, Haddix T, Sims L, Cheshier S, Chu P, Vogel H, Harsh G:
alpha(v)beta(3) Integrin in central nervous system tumors. Hum Pathol
2005, 36:665–669.
17. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I,
Schuch G: Cilengitide induces cellular detachment and apoptosis in
endothelial and glioma cells mediated by inhibition of FAK/src/AKT
pathway. J Exp Clin Cancer Res 2008, 27:86.
18. Jain RK, Di TE, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT:
Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610–622.
19. Batchelor TT, Sorensen AG, Di TE, Zhang WT, Duda DG, Cohen KS, Kozak KR,
Cahill DP, Chen PJ, Zhu M, et al: AZD2171, a pan-VEGF receptor tyrosine
kinase inhibitor, normalizes tumor vasculature and alleviates edema in
glioblastoma patients. Cancer Cell 2007, 11:83–95.
20. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R: Human
tumstatin and human endostatin exhibit distinct antiangiogenicactivities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc
Natl Acad Sci U S A 2003, 100:4766–4771.
21. Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG:
Endostatin blocks vascular endothelial growth factor-mediated signaling
via direct interaction with KDR/Flk-1. J Biol Chem 2002, 277:27872–27879.
22. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS,
Black PM: Continuous release of endostatin from microencapsulated
engineered cells for tumor therapy. Nat Biotechnol 2001, 19:35–39.
23. Schuch G, Machluf M, Bartsch G Jr, Nomi M, Richard H, Atala A, Soker S: In
vivo administration of vascular endothelial growth factor (VEGF) and its
antagonist, soluble neuropilin-1, predicts a role of VEGF in the
progression of acute myeloid leukemia in vivo. Blood 2002,
100:4622–4628.
24. Bartsch G Jr, Eggert K, Soker S, Bokemeyer C, Hautmann R, Schuch G:
Combined antiangiogenic therapy is superior to single inhibitors in a
model of renal cell carcinoma. J Urol 2008, 179:326–332.
25. Mariani TJ, Budhraja V, Mecham BH, Gu CC, Watson MA, Sadovsky Y: A
variable fold change threshold determines significance for expression
microarrays. FASEB J 2003, 17:321–323.
26. Johnson MP, Thompson SA, Lubaroff DM: Differential effects of prolactin
on rat dorsolateral prostate and R3327 prostatic tumor sublines. J Urol
1985, 133:1112–1120.
27. Manni A, Pontari M, Wright C: Autocrine stimulation by prolactin of
hormone-responsive breast cancer growth in culture. Endocrinology 1985,
117:2040–2043.
28. Brockman JL, Schroeder MD, Schuler LA: PRL activates the cyclin D1
promoter via the Jak2/Stat pathway. Mol Endocrinol 2002, 16:774–784.
29. Miller KD, Sweeney CJ, Sledge GW Jr: Can tumor angiogenesis be
inhibited without resistance? EXS 2005, 112:95–112.
30. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J:
Possible mechanisms of acquired resistance to anti-angiogenic drugs:
implications for the use of combination therapy approaches. Cancer
Metastasis Rev 2001, 20:79–86.
31. Glade BJ, Cooney EM, Kandel JJ, Yamashiro DJ: Vascular remodeling and
clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat
2004, 7:289–300.
32. Schuch G, Oliveira-Ferrer L, Loges S, Laack E, Bokemeyer C, Hossfeld DK,
Fiedler W, Ergun S: Antiangiogenic treatment with endostatin inhibits
progression of AML in vivo. Leukemia 2005, 19:1312–1317.
33. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR,
Hjelstuen MH, Haraldseth O, Bjerkvig R: Local endostatin treatment of
gliomas administered by microencapsulated producer cells. Nat
Biotechnol 2001, 19:29–34.
34. Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ,
Bergers G, Pieper RO: The PTEN/Akt pathway dictates the direct
alphaVbeta3-dependent growth-inhibitory action of an active fragment
of tumstatin in glioma cells in vitro and in vivo. Cancer Res 2006,
66:11331–11340.
35. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW,
Bigner DD, Rich JN: Glioma stem cells promote radioresistance by
preferential activation of the DNA damage response. Nature 2006,
444:756–760.
36. Bleau AM, Holland EC: [Chemotherapeutic treatment of gliomas increases
the amount of cancer stem-like cells]. Med Sci (Paris) 2009, 25:775–777.
37. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL,
Yu JS: Analysis of gene expression and chemoresistance of CD133+
cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
38. Clark PA, Iida M, Treisman DM, Kalluri H, Ezhilan S, Zorniak M, Wheeler DL,
Kuo JS: Activation of multiple ERBB family receptors mediates
glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Neoplasia 2012, 14:420–428.
39. Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE,
Ormandy CJ: Loss of mammary epithelial prolactin receptor delays tumor
formation by reducing cell proliferation in low-grade preinvasive lesions.
Oncogene 2007, 26:543–553.
40. Buckley AR, Putnam CW, Russell DH: Prolactin is a tumor promoter in rat
liver. Life Sci 1985, 37:2569–2575.
41. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman CC: In
vitro characterization of prolactin-induced effects on proliferation in the
neoplastic LNCaP, DU145, and PC3 models of the human prostate.
Cancer 1996, 7:144–149.
Oliveira-Ferrer et al. Molecular Cancer 2013, 12:144 Page 14 of 14
http://www.molecular-cancer.com/content/12/1/14442. Beck MT, Chen NY, Franek KJ, Chen WY: Prolactin antagonist-endostatin
fusion protein as a targeted dual-functional therapeutic agent for breast
cancer. Cancer Res 2003, 63:3598–3604.
43. DeVito WJ, Stone S, Mori K, Shamgochian M: Ethanol inhibits prolactin-
and tumor necrosis factor-alpha-, but not gamma interferon-induced
expression of intercellular adhesion molecule-1 in human astrocytoma
cells. J Cell Biochem 2000, 77:455–464.
44. Ciccarelli E, Razzore P, Gaia D, Todaro C, Longo A, Forni M, Ghe C, Camanni
F, Muccioli G, Faccani G, et al: Hyperprolactinaemia and prolactin binding
in benign intracranial tumours. J Neurosurg Sci 2001, 45:70–74.
45. Ducret T, Boudina S, Sorin B, Vacher AM, Gourdou I, Liguoro D, Guerin J,
Bresson-Bepoldin L, Vacher P: Effects of prolactin on intracellular calcium
concentration and cell proliferation in human glioma cells. Glia 2002,
38:200–214.
46. Galbaugh T, Feeney YB, Clevenger CV: Prolactin receptor-integrin cross-
talk mediated by SIRPalpha in breast cancer cells. Mol Cancer Res 2010,
8:1413–1424.
47. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI,
Martial JA: Opposing actions of intact and N-terminal fragments of the
human prolactin/growth hormone family members on angiogenesis: an
efficient mechanism for the regulation of angiogenesis. Proc Natl Acad
Sci U S A 1999, 96:1246–1251.
48. LaPensee EW, Schwemberger SJ, LaPensee CR, Bahassi EM, Afton SE, Ben
Jonathan N: Prolactin confers resistance against cisplatin in breast cancer
cells by activating glutathione-S-transferase. Carcinogenesis 2009,
30:1298–1304.
49. Sai Sato M, Nagashima Y, Miyagi E, Sato K, Ohta I, Vonderhaar BK, Hirahara F:
Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum
starvation or cisplatin treatment. Int J Cancer 2005, 115:539–544.
50. Hansen K, Wagner B, Hamel W, Schweizer M, Haag F, Westphal M, Lamszus
K: Autophagic cell death induced by TrkA receptor activation in human
glioblastoma cells. J Neurochem 2007, 103:259–275.
51. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ,
Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V,
Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA: Guidelines for the
welfare and use of animals in cancer research. Br J Cancer 2010,
102:1555–1577.
52. Oliveira Ferrer L, Wellbrock J, Braig M, Klokow M, Hauschild J, Bokemeyer C,
Fiedler W, Erguen S, Schuch G: The metabolite 3-hydroxiglutaric acid
effectively reduces glioblastoma growth in vivo by affecting the
structural integrity of tumor vasculature. Cancer Lett 2012, 326(2):161–167.
doi:10.1186/1476-4598-12-144
Cite this article as: Oliveira-Ferrer et al.: Combination therapy targeting
integrins reduces glioblastoma tumor growth through antiangiogenic and
direct antitumor activity and leads to activation of the pro-proliferative
prolactin pathway. Molecular Cancer 2013 12:144.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
